RIVER EDGE, N.J., Feb. 25 /PRNewswire-FirstCall/ -- Nephros, Inc. , a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today reported that is has signed an exclusive distribution agreement with Bellco Health Care Inc. (“BHC Medical”) to sell and market Nephros’ OLpur(TM) MD 220 filter for on-line HDF therapy in Canada.
“Bellco Medical is an ideal partner for the Canadian market,” said Ernest Elgin, President and CEO of Nephros. “They are a leading provider of End-Stage Renal Disease treatment systems who embrace leading-edge dialysis technologies such as our OLpur(TM) MD 220 HDF therapy.”
End-Stage Renal Disease (ESRD) Products
About BHC Medical
Bellco Health Care Inc. (BHC Medical), located in Toronto, Ontario Canada, is a leading provider of Renal Care Products to the Canadian healthcare community. As a marketing and support partner to several international manufacturers, BHC Medical offers a complete array of advanced medical devices, consumables, water treatment technologies, disinfectants and pharmaceuticals. For more information about BHC Medical, please visit their website at http://www.bhcmedical.ca.
About Nephros, Inc.
The Nephros hemodiafiltration (“HDF”) system is designed to improve the quality of life for the End-Stage Renal Disease (ESRD) patient while addressing the critical financial and clinical needs of the care provider. ESRD is a disease state characterized by the irreversible loss of kidney function. The Nephros HDF system removes a range of harmful substances more effectively, and with greater capacity, than existing ESRD treatment methods, particularly with respect to substances known collectively as “middle molecules.” These molecules have been found to contribute to such conditions as dialysis-related amyloidosis, carpal tunnel syndrome, degenerative bone disease and, ultimately, mortality in the ESRD patient. Nephros ESRD products are sold and distributed throughout Europe and are currently being used in over fifty clinics in Europe.
For more information about Nephros, please visit our website at http://www.nephros.com.
Statements in this news release that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Such statements may be preceded by words such as “may,” “plans,” “expects,” “believes,” “hopes,” “potential” or similar words. For such statements, Nephros claims the protection of the PSLRA.
CONTACT: Eileen Sukumaran, +1-201-343-5202, Eileen@nephros.com
Web site: http://www.nephros.com/
